Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma.

Autor: Meriranta L; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Sorri S; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Huse K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies and Precision Immunotherapy Alliance, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Liu X; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Spasevska I; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies and Precision Immunotherapy Alliance, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Zafar S; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Chowdhury I; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Dufva O; Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Sahlberg E; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Tandarić L; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Karjalainen-Lindsberg ML; Department of Pathology, Helsinki University Hospital, Helsinki, Finland., Hyytiäinen M; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Varjosalo M; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland., Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies and Precision Immunotherapy Alliance, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Leppä S; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.

Publikováno v: Blood cancer discovery [Blood Cancer Discov] 2024 Sep 03; Vol. 5 (5), pp. 331-352.

Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma.

Autor: Ludvigsen M; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark. majlud@rm.dk.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. majlud@rm.dk., Campbell AJ; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Enemark MB; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Hybel TE; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Karjalainen-Lindsberg ML; Department of Pathology, Helsinki University Hospital, Helsinki, Finland., Beiske K; Department of Pathology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Bjerre M; Medical/Steno Aarhus Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Pedersen LM; Zealand University Hospital, Roskilde, Denmark., Holte H; Department of Oncology, Oslo University Hospital, Oslo, Norway.; KG Jebsen Center for B-Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Norwegian Cancer Genomics Consortium, Oslo, Norway., Leppä S; Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Jørgensen JM; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Honoré B; Department of Biomedicine, Aarhus University, Aarhus, Denmark. bh@biomed.au.dk.

Publikováno v: Blood cancer journal [Blood Cancer J] 2023 Oct 26; Vol. 13 (1), pp. 161. Date of Electronic Publication: 2023 Oct 26.

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.

Autor: Meriranta L; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Alkodsi A; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Pasanen A; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Lepistö M; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science HILIFE, Helsinki, Finland., Mapar P; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science HILIFE, Helsinki, Finland., Blaker YN; Department of Oncology, Oslo University Hospital and KG Jebsen Centre for B Cell Malignancies, Oslo, Norway., Jørgensen J; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Karjalainen-Lindsberg ML; Department of Pathology, Helsinki University Hospital, Helsinki, Finland., Fiskvik I; Department of Radiology and Nuclear Medicine., Mikalsen LTG; Department of Diagnostic Physics, Oslo University Hospital, Oslo, Norway.; Department of Life Sciences and Health, Oslo Metropolitan University, Oslo, Norway., Autio M; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Björkholm M; Department of Medicine, Karolinska University Hospital, Stockholm, Sweden., Jerkeman M; Division of Oncology, Skane University Hospital, Lund, Sweden., Fluge Ø; Department of Oncology, Haukeland University Hospital, Bergen, Norway., Brown P; Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; and., Jyrkkiö S; Department of Oncology, Turku University Hospital, Turku, Finland., Holte H; Department of Oncology, Oslo University Hospital and KG Jebsen Centre for B Cell Malignancies, Oslo, Norway., Pitkänen E; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science HILIFE, Helsinki, Finland., Ellonen P; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science HILIFE, Helsinki, Finland., Leppä S; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.

Publikováno v: Blood [Blood] 2022 Mar 24; Vol. 139 (12), pp. 1863-1877.

Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment.

Autor: Autio M; Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Leivonen SK; Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Brück O; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Karjalainen-Lindsberg ML; Department of Pathology, Helsinki University Hospital, Helsinki, Finland., Pellinen T; Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland., Leppä S; Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Feb 15; Vol. 28 (4), pp. 781-792.

Ischemic Stroke: Pathophysiology and Evolving Treatment Approaches.

Autor: Majumder, Dhriti¹ (AUTHOR) dhriti2004@gmail.com

Publikováno v: Neuroscience Insights. 10/22/2024, p1-8. 8p.